OBJECTIVE: The safe and efficacious use of Pycnogenol (French maritime pine bark extract) in other inflammatory diseases prompted this study of its antiinflammatory effects in patients with osteoarthritis (OA). The aim of the study was to evaluate whether Pycnogenol reduces the symptoms of OA in a double-blind, placebo-controlled, randomly allocated trial with patients suffering from knee osteoarthritis stages I and II. METHODS:100 patients were treated for 3 months either by 150 mg Pycnogenol per day at meals or by placebo. Patients had to report any change of use of previously prescribed antiinflammatory medication during the study period. Patients filled the Western Ontario and Mc Masters University (WOMAC) questionnaire for osteoarthritis every 2 weeks and evaluated weekly pain symptoms using a visual analogue scale for pain intensity. RESULTS: Following treatment with Pycnogenol patients reported an improvement of WOMAC index (p < 0.05), and a significant alleviation of pain by visual analogue scale (p < 0.04), the placebo had no effect. The use of analgesics diminished in the verum group but increased under the placebo. Treatment with Pycnogenol was well tolerated. CONCLUSION: Results show that Pycnogenol in patients with mild to moderate OA improves symptoms and is able to spare NSAIDs.
RCT Entities:
OBJECTIVE: The safe and efficacious use of Pycnogenol (French maritime pine bark extract) in other inflammatory diseases prompted this study of its antiinflammatory effects in patients with osteoarthritis (OA). The aim of the study was to evaluate whether Pycnogenol reduces the symptoms of OA in a double-blind, placebo-controlled, randomly allocated trial with patients suffering from knee osteoarthritis stages I and II. METHODS: 100 patients were treated for 3 months either by 150 mg Pycnogenol per day at meals or by placebo. Patients had to report any change of use of previously prescribed antiinflammatory medication during the study period. Patients filled the Western Ontario and Mc Masters University (WOMAC) questionnaire for osteoarthritis every 2 weeks and evaluated weekly pain symptoms using a visual analogue scale for pain intensity. RESULTS: Following treatment with Pycnogenolpatients reported an improvement of WOMAC index (p < 0.05), and a significant alleviation of pain by visual analogue scale (p < 0.04), the placebo had no effect. The use of analgesics diminished in the verum group but increased under the placebo. Treatment with Pycnogenol was well tolerated. CONCLUSION: Results show that Pycnogenol in patients with mild to moderate OA improves symptoms and is able to spare NSAIDs.
Authors: Stephen P Myers; Joan O'Connor; J Helen Fitton; Lyndon Brooks; Margaret Rolfe; Paul Connellan; Hans Wohlmuth; Phil A Cheras; Carol Morris Journal: Biologics Date: 2010-03-24
Authors: Bruce P Burnett; Alessandra Bitto; Domenica Altavilla; Francesco Squadrito; Robert M Levy; Lakshmi Pillai Journal: Mediators Inflamm Date: 2011-06-19 Impact factor: 4.711
Authors: Paola Castrogiovanni; Francesca Maria Trovato; Carla Loreto; Houda Nsir; Marta Anna Szychlinska; Giuseppe Musumeci Journal: Int J Mol Sci Date: 2016-12-06 Impact factor: 5.923
Authors: Angela Wang; Daniel J Leong; Zhiyong He; Lin Xu; Lidi Liu; Sun Jin Kim; David M Hirsh; John A Hardin; Neil J Cobelli; Hui B Sun Journal: Int J Mol Sci Date: 2016-12-09 Impact factor: 5.923